InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,460.48
(
-0.41%
)
US TECH 100
19,181.60
(
-0.43%
)
Dow Jones
39,118.86
(
-0.12%
)
Brent Oil
84.85
(
0.00%
)
Bitcoin
60,972.22
(
1.09%
)
Post# of 252427
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

jq1234

Send PM Follow Ignore
Followers 68
Posts 4505
Boards Moderated 0
Alias Born 12/13/2009

jq1234

Re: jaybe post# 178021

Friday, 05/16/2014 11:42:46 PM

Friday, May 16, 2014 11:42:46 PM

Post# of 252427
I don't think it is taking market share question as PD1 might have difficulty proving better than targeted therapies for EGFRm and ALK+ NSCLC based on results we have seen so far, rather potential combination usage. Roche might agree with correlation view as it is the first company to combine its PDL1 with erlotinib for EGFRm and MEKi cobimetinib for KRAS.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up